PROKIDNEY CORP.

ProKidney Corp. (NASDAQ: DNAC) is a clinical-stage biotherapeutics company focused on regenerative cell therapy for chronic kidney disease. The company entered the public markets through a business combination with Social Capital Suvretta Holdings Corp. III, a blank-check vehicle sponsored by Social Capital Suvretta that completed its IPO in 2021. The merger closed in 2022, establishing ProKidney as a publicly traded entity under the DNAC ticker in the healthcare and life sciences sector. The company filed an 8-K current report with the SEC on May 30, 2025, representing its latest disclosure as a post-merger public company. For full filing history, deal terms, and real-time analytics on ProKidney and hundreds of other de-SPAC companies, sign up for SpacDesk at spacdesk.com.